Summit Financial LLC Sells 236 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Summit Financial LLC trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 11.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,803 shares of the biotechnology company’s stock after selling 236 shares during the quarter. Summit Financial LLC’s holdings in Sarepta Therapeutics were worth $219,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Captrust Financial Advisors increased its holdings in shares of Sarepta Therapeutics by 15.2% in the 3rd quarter. Captrust Financial Advisors now owns 3,871 shares of the biotechnology company’s stock valued at $483,000 after acquiring an additional 511 shares during the period. Stifel Financial Corp raised its holdings in Sarepta Therapeutics by 99.3% in the third quarter. Stifel Financial Corp now owns 37,207 shares of the biotechnology company’s stock worth $4,647,000 after purchasing an additional 18,537 shares in the last quarter. Soros Fund Management LLC purchased a new stake in shares of Sarepta Therapeutics during the third quarter valued at about $25,800,000. Wellington Management Group LLP boosted its holdings in shares of Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC grew its position in shares of Sarepta Therapeutics by 36.7% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 2,814 shares of the biotechnology company’s stock worth $322,000 after buying an additional 755 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $54.43 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a twelve month low of $54.26 and a twelve month high of $173.25. The stock has a 50-day moving average of $96.95 and a 200 day moving average of $113.78. The stock has a market capitalization of $5.28 billion, a price-to-earnings ratio of 43.54 and a beta of 0.79.

Analyst Upgrades and Downgrades

SRPT has been the subject of a number of analyst reports. Needham & Company LLC decreased their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating for the company in a research report on Thursday. Deutsche Bank Aktiengesellschaft lowered their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th. HC Wainwright upgraded Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 target price on the stock in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Finally, Scotiabank dropped their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research note on Thursday, March 20th. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $163.18.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.